.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 4,138,415

« Back to Dashboard

Claims for Patent: 4,138,415

Title: 1,4-Bis(aminoalkylamino)-anthraquinones and leuco derivatives thereof
Abstract:This disclosure describes 1,4-bis(substituted-amino)-5,6-dihydroxyanthraquinones and 1,4,5-tris(substituted-amino)-8-hydroxyanthraquinones useful as chelating agents, as curing catalysts for epoxy resins, and for inhibiting the growth of transplanted mouse tumors.
Inventor(s): Murdock; Keith C. (Pearl River, NY), Child; Ralph G. (Pearl River, NY)
Assignee: American Cyanamid Company (Stamford, CT)
Application Number:05/903,292
Patent Claims: 1. A compound selected from the group consisting of those of the formula: ##STR5## wherein R.sub.1 and R.sub.2 are each individually selected from the group consisting of hydrogen, methyl, ethyl and 2-hydroxyethyl; R.sub.3 is hydrogen or hydroxy; R.sub.4 is hydrogen or a moiety of the formula: ##STR6## wherein R.sub.1 and R.sub.2 are as hereinabove defined with the proviso that one of R.sub.3 and R.sub.4 must be hydrogen but R.sub.3 and R.sub.4 may not both be hydrogen; and the pharmacologically acceptable acid-addition salts thereof.

2. A compound selected from the group consisting of those of the formula: ##STR7## wherein R.sub.1 and R.sub.2 are each individually selected from the group consisting of hydrogen, methyl, ethyl and 2-hydroxyethyl; R.sub.3 is hydrogen or hydroxy; R.sub.4 is hydrogen or a moiety of the formula: ##STR8## wherein R.sub.1 and R.sub.2 are as hereinabove defined with the proviso that one of R.sub.3 and R.sub.4 must be hydrogen but R.sub.3 and R.sub.4 may not both be hydrogen; the tautomers thereof; and the pharmacologically acceptable acid-addition salts thereof.

3. The compound according to claim 1 wherein R.sub.1 and R.sub.2 are both methyl, R.sub.3 is hydrogen, and R.sub.4 is 2-dimethylaminoethylamino; 1,4,5-tris[(2-dimethylaminoethyl)amino]-8-hydroxyanthraquinone.

4. The compound according to claim 1 wherein R.sub.1 and R.sub.2 are both hydrogen, R.sub.3 is hydroxy, and R.sub.4 is hydrogen; 1,4-bis[(2-aminoethyl)amino]-5,6-dihydroxyanthraquinone.

5. The compound according to claim 2 wherein R.sub.1 and R.sub.2 are both ethyl, R.sub.3 is hydrogen, and R.sub.4 is 2-diethylaminoethylamino; leuco-1,4,5-tris[(2-diethylaminoethyl)amino]-8-hydroxyanthraquinone.

6. The compound according to claim 2 wherein R.sub.1 is hydrogen, R.sub.2 is ethyl, R.sub.3 is hydroxy, and R.sub.4 is hydrogen; leuco-1,4-bis[(2-ethylaminoethyl)amino]-5,6-dihydroxyanthraquinone.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc